Center Laboratories to ‘unblind’ diabetes drug dataBy Kao Shih-ching / Staff reporterCenter Laboratories Inc (晟德大藥廠) yesterday said that it plans to “unblind” the data from the phase II clinical trial of its diabetes drug candidate CS02 in the second half of this year, after completing the “last patient’s last visit” late last month. The firm would collect and unblind the data to see if the experimental drug is safe and effective, general manager Robert Hsu (許瑞寶) told the Taipei Times by telephone. All of the enrolled patients were type 2 diabetes patients for whom the first-line treatment metformin proved ineffective, he said. Center Laboratories aims to market CS02 as a second-line treatment for people with type 2 diabetes, Hsu said. “We would focus on the two gauges for the time being, given that global regulators have not set official gauges for the assessment of type 2 diabetes patients,” he said.

Source: Taipei Times May 05, 2020 15:56 UTC